Description: <b>Dandelion root</b> (Taraxacum officinale) <br>
-Various phytochemicals, including flavonoids and phenolic compounds, which have antioxidant properties.<br>
-Root extract can induce apoptosis<br>
-Anti-inflammatory properties<br>
-Immune System Support<br>
Dosage: dried root 2-8g/d. Extract 250-500mg/d Tea 1-2g, 1-3x/d<br>
aqueous Dandelion flower extracts (DFE), dandelion leaf extract (DLE), and dandelion root extract (DRE) may have different effects.<br>
Common Names: Blowball, Puffball, Lion's tooth, Pu gong ying, Swine snout, Wild endive<br>
Taraxacum officinale is rich in flavonoids (e.g., luteolin, quercetin glycosides), phenolic acids (chicoric, chlorogenic, and caffeic acids), terpenoids (taraxasterol, taraxerol), sesquiterpene lactones (taraxinic acid β-D-glucopyranosyl ester), and phytosterols (β-sitosterol, cycloartenol) <br>
-dandelion leaf, cichoric acid is more relevant than in the root (~7.7 mg/g dry leaf)<br>
<p><b>Dandelion Root</b> — Dandelion root is the root material or root extract of <i>Taraxacum officinale</i>, a polychemical botanical preparation containing phenolic acids, flavonoids, sesquiterpene lactones, triterpenes, inulin-type carbohydrates, and other phytochemicals. It is formally classified as a botanical dietary supplement or herbal extract rather than a defined single-molecule oncology drug. Standard abbreviations include DRE for dandelion root extract and <i>T. officinale</i> for the plant species. Current oncology relevance is mainly preclinical, with repeated in-vitro and xenograft signals but no completed convincing human cancer efficacy trial.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Selective programmed cell death induction in cancer cells, especially extrinsic caspase-8 signaling with downstream mitochondrial destabilization and caspase execution.</li>
<li>Mitochondrial stress and pro-death autophagy, including loss of mitochondrial integrity and context-dependent mitochondrial ROS involvement.</li>
<li>Multi-pathway growth suppression through cell-cycle disruption, PI3K-Akt/JAK-STAT/PPAR pathway modulation, and reduced survival signaling.</li>
<li>Anti-invasive and anti-metastatic signaling, including reduced migration/invasion phenotypes and reduced MMP-9/IL-1β expression in some models.</li>
<li>Chemosensitization or adjunctive enhancement in preclinical models, especially with taxol and mitoxantrone in prostate cancer models.</li>
<li>Anti-inflammatory and antioxidant effects in non-cancer contexts; these are biologically relevant but not the central cancer-killing mechanism.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Dandelion root extract is not a standardized single active agent, so formal human PK is not well established. Oral use is plausible as a botanical preparation, but systemic exposure to the same complex extract composition used in cell culture is unknown. Inulin-rich root material may also act partly through gastrointestinal or microbiome-facing exposure rather than direct plasma-equivalent exposure.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many anticancer experiments use crude extract concentrations in the mg/mL range and exposure windows of 24–96 hours. These concentrations should not be assumed to be systemically achievable after oral use. Colorectal and gastrointestinal tumor models may have relatively better luminal-exposure plausibility than distant solid-tumor systemic exposure, but clinical translation remains unproven.</p>
<p><b>Clinical evidence status:</b> Preclinical. Evidence includes cell-line studies, some xenograft studies, and case-report-level human observations. A phase I cancer trial effort was reported as Health Canada-approved/recruiting, but there is no clear completed trial demonstrating cancer efficacy. It should not be treated as an established anticancer therapy.</p>
<p><b>Safety / deployment status:</b> Dandelion is widely marketed as a food/herbal dietary supplement and is generally considered likely safe at food-level intake, but concentrated medicinal doses have less safety evidence. Important constraints include possible allergy in Asteraceae-sensitive individuals, theoretical interactions with antidiabetic, anticoagulant/antiplatelet, lithium, diuretic, and other medications, and uncertainty in pregnancy or breastfeeding. Hormone-sensitive cancer caution is reasonable because some preclinical evidence suggests estrogenic activity and possible stimulation of hormone-sensitive breast cancer models.</p>
<h3>Dandelion Root Cancer Mechanism Table</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Extrinsic apoptosis and caspase activation</td>
<td>↑ caspase-8, ↑ Annexin V positivity, ↑ programmed cell death</td>
<td>↔ or lower toxicity in tested PBMCs, fibroblasts, colon mucosa, and mammary epithelial cells</td>
<td>G</td>
<td>Selective cancer-cell apoptosis</td>
<td>Most central recurring anticancer signal across melanoma, leukemia, colorectal, pancreatic, prostate, and breast models; strongest evidence remains in vitro.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial destabilization</td>
<td>↓ mitochondrial integrity, ↓ mitochondrial membrane potential, ↑ downstream death signaling</td>
<td>↔ or relatively spared in several comparator normal-cell models</td>
<td>G</td>
<td>Amplifies intrinsic death execution</td>
<td>Mitochondrial injury appears downstream of extrinsic death signaling in some leukemia models and more direct in melanoma/pancreatic models.</td>
</tr>
<tr>
<td>3</td>
<td>Pro-death autophagy</td>
<td>↑ autophagy with apoptosis linkage</td>
<td>↔ uncertain</td>
<td>G</td>
<td>Contributes to programmed cell death</td>
<td>Reported in CMML and pancreatic cancer studies; autophagy direction should be interpreted as pro-death in those models, not automatically cytoprotective.</td>
</tr>
<tr>
<td>4</td>
<td>Cell cycle arrest</td>
<td>↑ S phase and G2/M accumulation, ↓ proliferation</td>
<td>↔ or less affected in tested normal mammary epithelial cells</td>
<td>G</td>
<td>Restricts proliferation</td>
<td>Best supported in newer breast cancer fractionation/proteomics work; extract-specific and concentration-dependent.</td>
</tr>
<tr>
<td>5</td>
<td>PI3K-Akt and JAK-STAT survival signaling</td>
<td>↓ PI3K/Akt-related survival proteins, ↓ JAK/STAT-associated signaling markers (model-dependent)</td>
<td>↔ uncertain</td>
<td>G</td>
<td>Reduces survival signaling</td>
<td>Mechanistic support is strongest in MDA-MB-231 fraction studies; requires caution because crude extracts and fractions differ substantially.</td>
</tr>
<tr>
<td>6</td>
<td>Mitochondrial ROS increase secondary</td>
<td>↑ ROS (context-dependent), ↑ oxidative mitochondrial stress</td>
<td>↔ uncertain; antioxidant effects may occur in normal inflammatory injury models</td>
<td>R/G</td>
<td>Stress-mediated death amplification</td>
<td>ROS is not uniformly the primary DRE mechanism; in prostate work, DRE apoptosis was described as caspase-dependent while lemongrass was more ROS-dependent.</td>
</tr>
<tr>
<td>7</td>
<td>Migration invasion and metastasis markers</td>
<td>↓ migration, ↓ invasion, ↓ MMP-9, ↓ IL-1β, ↑ KAI1 (model-dependent)</td>
<td>↔ uncertain</td>
<td>G</td>
<td>Anti-invasive phenotype</td>
<td>Observed in breast and pediatric/neuroblastoma models; translational strength is lower than the apoptosis signal.</td>
</tr>
<tr>
<td>8</td>
<td>Chemosensitization</td>
<td>↑ taxol-induced apoptosis, ↑ mitoxantrone-induced apoptosis, ↓ xenograft tumor burden with oral extract in prostate models</td>
<td>↔ or reduced toxicity signal in selected comparator normal-cell assays</td>
<td>G</td>
<td>Adjunctive enhancement</td>
<td>Preclinical adjunct signal only; drug interaction risk means this should not be assumed safe with chemotherapy without oncology supervision.</td>
</tr>
<tr>
<td>9</td>
<td>Inflammation and NF-κB linked signaling</td>
<td>↓ inflammatory signaling markers (context-dependent)</td>
<td>↓ inflammatory injury markers in non-cancer models</td>
<td>G</td>
<td>Anti-inflammatory modulation</td>
<td>Relevant to tumor microenvironment hypotheses but less directly established as a dominant cancer-cell killing mechanism for root extract.</td>
</tr>
<tr>
<td>10</td>
<td>NRF2 antioxidant axis</td>
<td>↔ insufficient direct cancer-specific evidence for root extract</td>
<td>↑ antioxidant defense may occur in injury/metabolic models (context-dependent)</td>
<td>G</td>
<td>Not a core cancer axis</td>
<td>Do not tag NRF2 as a primary DRE anticancer mechanism unless a specific study directly supports it in the target cancer model.</td>
</tr>
<tr>
<td>11</td>
<td>Clinical Translation Constraint</td>
<td>High in-vitro extract concentrations; variable extract chemistry; no validated human anticancer exposure target</td>
<td>Food-level safety generally favorable but concentrated-dose interaction and allergy concerns remain</td>
<td>G</td>
<td>Limits clinical inference</td>
<td>Evidence is promising but mostly preclinical; oral dosing cannot be translated directly from mg/mL cell-culture exposure.</td>
</tr>
</tbody>
</table>
<p>TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr</p>